The Cooper Companies, Inc. (NASDAQ:COO) cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected demand for contact lenses weighed on its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from its previous forecast of $4.58–$4.66, while revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate, although adjusted EPS of $1.15 beat expectations.
The weakness was concentrated in CooperVision, where revenue fell to $717 million. Cooper said a reduction in U.S. channel inventory hurt results and is expected to continue affecting the fourth quarter. At the same time, the company completed its strategic review and decided to retain CooperSurgical rather than sell the business.
The biggest bullish argument is that some of the current weakness may be temporary rather than a fundamental deterioration in the contact lens market. The Cooper Companies, Inc. (NASDAQ:COO) specifically pointed to U.S. channel inventory reductions, meaning part of the sales pressure reflects distributors and customers working through existing stock rather than consumers permanently abandoning contact lenses. If inventories normalize, CooperVision could see a recovery in sales growth.
Cooper also continues to have a strong position in the global contact lens market. The company is investing in new products, expanding CooperVision's sales and marketing organization and improving inventory and logistics operations. Its strategic review also identified opportunities to reduce costs and improve operational efficiency.
There are encouraging signs beneath the weak headline numbers. Adjusted third-quarter EPS still increased 4% year over year to $1.15, while free cash flow jumped 66% to $273 million. The Cooper Companies, Inc. (NASDAQ:COO) also increased its share-repurchase authorization from $2 billion to $3 billion, giving the company another way to support per-share earnings if the stock remains depressed.

#Companies #revenue #contact #coopervision

The Cooper Companies Inc. (NASDAQ:COO), a leading medical device company, announced its third quarter fiscal 2026 results on September 9. Topline went up 1% to $1.066 billion in comparison with the same quarter last year, which also included 1% organic growth. The company posted quarterly adjusted diluted EPS of $1.15, which represented a 4% jump from Q3 FY25. During the quarter, $339.1 million was spent on repurchasing around 4.9 million of the company's common shares. This leaves management with $1.5 billion of repurchase capacity, which remains available after the Board had raised its buyback authorization from $2 billion to $3 billion.
The quarter featured several encouraging highlights. These include earnings that exceeded projections, notable growth across the fertility segment within CooperSurgical, record free cash flow generation, and a major tax resolution in the company's favor.
GAAP gross margin went up from 65% in Q3 FY25 to 67% during the recent quarter, largely reflecting the comparison against fiscal 2025 inventory write-downs tied to a CooperSurgical product line exit. Adjusted operating margin improved by 30 basis points to 26%, supported by cost discipline and productivity gains, though partly offset by currency headwinds.
Interest expense fell to $21.5 million from $25.4 million a year prior, reflecting lower rates and reduced average debt. Free cash flow surged 66% to $273.0 million, driven by $341.7 million in operating cash flow less $68.7 million in capital spending.
Due to unfavorable currency movements and rising manufacturing costs, the Q3 gross margin settled at 67% on adjusted basis. This was a 60 basis point drop from Q3 FY25. Certain areas of the business grant caution, such as the CooperVision segment. It generated flat organic growth amid notable weakness across the Asia Pacific and Americas regions.

#billion #cash

Investors hammered Cooper Companies (COO) on Thursday after the medtech's fiscal third-quarter sales lagged Wall Street's expectations, leading to a guidance cut.
Specifically, the CooperVision segment — which sells contact lenses — missed expectations by 4.5%, William Blair **** yst Steven Lichtman said in a report. The miss was due to destocking. Further, the company opted against selling its CooperSurgical business following a strategic review.
"The 'no sale' is a surprise after management highlighted prospective buyers on the last earnings call," he said. "With CVI (CooperVision) results also disappointing, the stock moves back into the penalty box."
On today's stock market, Cooper Companies shares toppled 14.7%, closing at 54.17. Shares are already trading well below their key moving averages, IBD MarketSurge charts show.
Cooper said it couldn't sell the surgical division due to competition for its implantable contraceptive, Paragard, an intrauterine device. In June, Organon (OGN) licensed Miudella, a rival to Cooper's non-hormonal IUD. Cooper is also facing fertility litigation, BofA Securities **** yst Travis Steed said in a note to clients.

#Companies #expectations #investors #wall

San Ramon, California-based The Cooper Companies, Inc. (COO) develops, manufactures, and markets contact lenses for wearers. The company has a market cap of $14.9 billion and operates in two segments, CooperVision and CooperSurgical, and offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia, and more.
Shares of Cooper Companies have lagged behind the broader market over the past year, growing 1.6% compared to the S&P 500 Index's ($SPX) 20.5% surge. Moreover, in 2026, the stock has fallen by nearly 6.7%, also underperforming SPX's 12.1% gain.
Soros Fund Management Opened a New Position in Nebius During Q2. What This Means for NBIS Stock.
Nvidia Earnings, Jackson Hole and Other Key Things to Watch this Week
Ahead of Nvidia Earnings, Here's What Barchart Data Says Comes Next for NVDA Stock

#california

Harris Oakmark recently released its second-quarter 2026 investor letter for the "Oakmark Global Fund". A copy of the letter can be downloaded here. It is a non-diversified fund that focuses on long-term capital appreciation by investing in common stocks of U.S. and non-U.S. companies. In the second quarter, the fund (Investor Class) delivered a return of 7.89%, lagging the benchmark, the MSCI World Index's 13.76% return. Energy and industrials were the top performance contributors at the sector level, while health care and consumer discretionary detracted from performance. AI remains a key market theme. The firm focuses on evaluating companies based on their competitive advantages, long-term cash flow potential, and valuation, not predictions. In addition, you can check the Fund's top five holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, Oakmark Global Fund highlighted TheCooper Companies, Inc. (NASDAQ:COO) as a newly added position. The Cooper Companies, Inc. (NASDAQ:COO) is a medical device company that operates through CooperVision and CooperSurgical segments. On July 14, 2026, The Cooper Companies, Inc. (NASDAQ:COO) closed at $68.51 per share. One-month return of The Cooper Companies, Inc. (NASDAQ:COO) was 7.35%, and its shares lost 3.95% over the past 52 weeks. The Cooper Companies, Inc. (NASDAQ:COO) has a market capitalization of $13.36 billion.
Oakmark Global Fund stated the following regarding The Cooper Companies, Inc. (NASDAQ:COO) in its Q2 2026 investor update:
"The Cooper Companies, Inc. (NASDAQ:COO) is a U.S.-headquartered medical device company that manufactures contact lenses and women's health products. The contact lens industry benefits from an oligopolistic market structure with significant barriers to entry, highly recurring revenue streams, and historically has consistently positive pricing dynamics that support mid single-digit market growth over time. Cooper has an impressive track record of contact lens market share gains, which we attribute to its leading position in specialty lenses and its unique private-label strategy. We are encouraged by recent steps taken to improve free cash flow conversion, reaccelerate growth, and optimize the product portfolio. The stock has pulled back sharply alongside the broader medical technology sector and now trades at a meaningful discount to public peers, private market transactions, and its own trading history. We were pleased to initiate a position at what we view as an attractive entry point relative to our estimate of intrinsic value."

San Ramon, California-based The Cooper Companies, Inc. (COO) develops, manufactures, and markets contact lens wearers. The company has a market cap of $13.2 billion and operates in two segments, CooperVision and CooperSurgical, and offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia, and more.
Companies with a market cap of $10 billion or more are typically referred to as "big-cap stocks." COO fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical instruments and supplies industry.
Dear Rocket Lab Stock Fans, Mark Your Calendars for June 22
Stay Away from Super Micro Computer Stock. It's Hostage to Its Own Mistakes.
Palantir Stock Is Down Nearly 30% in 2026. Here's What It Will Take to Turn Around.